These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27852960)

  • 21. The pharmacology of the psychoactive drugs.
    Cohen S
    Northwest Med; 1966 Mar; 65(3):197-203. PubMed ID: 5907893
    [No Abstract]   [Full Text] [Related]  

  • 22. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The psychopharmacology of hallucinogens.
    Abraham HD; Aldridge AM; Gogia P
    Neuropsychopharmacology; 1996 Apr; 14(4):285-98. PubMed ID: 8924196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Psychotropic drug prescription in adolescent].
    Laget J
    Rev Med Suisse Romande; 2000 Feb; 120(2):117-22. PubMed ID: 10748697
    [No Abstract]   [Full Text] [Related]  

  • 25. MDMA: interactions with other psychoactive drugs.
    Mohamed WM; Ben Hamida S; Cassel JC; de Vasconcelos AP; Jones BC
    Pharmacol Biochem Behav; 2011 Oct; 99(4):759-74. PubMed ID: 21756931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Side effects and therapeutic effects.
    Kramer T
    MedGenMed; 2003 Jan; 5(1):28. PubMed ID: 12827089
    [No Abstract]   [Full Text] [Related]  

  • 27. Set, setting, and matrix.
    Eisner B
    J Psychoactive Drugs; 1997; 29(2):213-6. PubMed ID: 9250949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The psychodynamic psychopharmacology by D. Mintz and B. Belnap--description of discipline in relation with treatment resistance].
    Murawiec S
    Psychiatr Pol; 2008; 42(3):323-33. PubMed ID: 19899561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uncovering psychological mechanisms mediating the effects of drugs: some issues and comments using the example of psychedelic drugs.
    Kangaslampi S
    Psychopharmacology (Berl); 2020 Dec; 237(12):3799-3802. PubMed ID: 33151375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction to 'beneficial effects of psychedelics with a special focus on addictions'.
    Breeksema JJ; Kortekaas R
    Curr Drug Abuse Rev; 2014; 7(3):135. PubMed ID: 25870868
    [No Abstract]   [Full Text] [Related]  

  • 32. Serotonergic psychedelics temporarily modify information transfer in humans.
    Alonso JF; Romero S; Mañanas MÀ; Riba J
    Int J Neuropsychopharmacol; 2015 Mar; 18(8):. PubMed ID: 25820842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost of treatment as a placebo effect in psychopharmacology: importance in the context of generic drugs.
    Andrade C
    J Clin Psychiatry; 2015 Apr; 76(4):e534-6. PubMed ID: 25919852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Psychopharmacotherapy in the adult psychiatric domain].
    Bryois C
    Rev Med Suisse Romande; 2000 Feb; 120(2):123-9. PubMed ID: 10748698
    [No Abstract]   [Full Text] [Related]  

  • 35. Back to the future of psychopharmacology: A perspective on animal models in drug discovery.
    Hendriksen H; Groenink L
    Eur J Pharmacol; 2015 Jul; 759():30-41. PubMed ID: 25814259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects.
    Caudevilla-Gálligo F; Riba J; Ventura M; González D; Farré M; Barbanoj MJ; Bouso JC
    J Psychopharmacol; 2012 Jul; 26(7):1026-35. PubMed ID: 22234927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychopharmacologic treatment in juvenile offenders.
    Soller MV; Karnik NS; Steiner H
    Child Adolesc Psychiatr Clin N Am; 2006 Apr; 15(2):477-99, x. PubMed ID: 16527667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hallucinogenic substances. Their role in research and in current psychiatric therapy].
    Benoit JC
    Sem Ther; 1965 Jan; 41(1):28-33. PubMed ID: 5879030
    [No Abstract]   [Full Text] [Related]  

  • 39. [Antagonists of ionotropic glutamate receptors as the object of research in psychopharmacology].
    Bespalov AIu; Evartau EE
    Usp Fiziol Nauk; 1999; 30(1):39-53. PubMed ID: 10205818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychodynamic psychopharmacotherapy and application of "brain-mind" concept.
    Vlastelica M; Jelaska M; Matijević V
    Psychiatr Danub; 2011 Sep; 23(3):286-8. PubMed ID: 21963698
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.